Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical Features

BACKGROUND AND PURPOSE: Hemorrhage is known to occur in posterior reversible encephalopathy syndrome (PRES), but the characteristics have not been analyzed in detail. The purpose of this study was to evaluate the imaging and clinical features of hemorrhage in PRES.

MATERIALS AND METHODS: Retrospective assessment of 151 patients with PRES was performed, and 23 patients were identified who had intracranial hemorrhage at toxicity. Hemorrhage types were identified and tabulated, including minute focal hemorrhages (<5 mm), sulcal subarachnoid hemorrhage, and focal hematoma. Clinical features of hemorrhage and nonhemorrhage PRES groups were evaluated, including toxicity blood pressure, coagulation profile/platelet counts, coagulation-altering medication, and clinical conditions associated with PRES. Toxicity mean arterial pressure (MAP) groups were defined as normal (<106 mm Hg), mildly hypertensive (106–116 mm Hg), or severely hypertensive (>116 mm Hg).

RESULTS: The overall incidence of hemorrhage was 15.2%, with borderline statistical significance noted between the observed clinical associations (P = .07). Hemorrhage was significantly more common (P = .02) after allogeneic bone marrow transplantation (allo-BMT) than after solid-organ transplantation. The 3 hemorrhage types were noted with equal frequency. A single hemorrhage type was found in 16 patients, with multiple types noted in 7. Patients undergoing therapeutic anticoagulation were statistically more likely to develop hemorrhage (P = .04). No difference in hemorrhage incidence was found among the 3 blood pressure subgroups (range, 14.9%–15.9%).

CONCLUSIONS: Three distinct types of hemorrhage (minute hemorrhage, sulcal subarachnoid hemorrhage, hematoma) were identified in PRES with equal frequency. The greatest hemorrhage frequency was seen after allo-BMT and in patients undergoing therapeutic anticoagulation. Hemorrhage rate was independent of the toxicity blood pressure.

Posterior reversible encephalopathy syndrome (PRES) is characterized by a variety of symptoms ranging from headache, altered mental status, and visual loss to seizures and loss of consciousness, accompanied by a typical CT or MR imaging pattern.1–8 The imaging appearance was originally noted in patients with preeclampsia/eclampsia, after transplantation (solid-organ transplantation or allogeneic bone marrow transplantation [allo-BMT]), or in the setting of severe hypertension.9–23 The wider spectrum of patients who develop this toxicity was highlighted by Hinchey et al in 199624 and the term “PRES” was used to characterize the typical and unique imaging appearance. The mechanism of PRES is not yet determined; however, it is thought to be related to endothelial cell dysfunction/injury leading to blood-brain barrier leakage, with resultant cortical and subcortical vasogenic edema.4,17,25–29

Intracranial hemorrhage is known to occur in PRES; however, no study has comprehensively focused on this subgroup of patients with PRES. The purpose of this study was to assess the clinical and imaging features of patients with PRES and hemorrhage.

Materials and Methods

The radiology report data base at our institution was searched from January 1998 to August 2007 for any patients in whom “PRES” or “posterior reversible encephalopathy” was noted on brain MR imaging. Additional searches were performed for other conditions known to lead to or be associated with PRES, including the following: cyclosporine neurotoxicity, Tacrolimus (FK-506) neurotoxicity, systemic lupus erythematosus, scleroderma, and hypertensive encephalopathy.

The scope of the imaging features seen in PRES has been described previously.1,3,5,30 Brain CT/MR imaging studies were reviewed in the identified patients for features consistent with the characteristics of cyclosporine/Tacrolimus (FK-506) neurotoxicity syndrome, eclampsia, or PRES. Cases were included by consensus agreement between 2 experienced neuroradiologists. Criteria for confirmation of PRES included complete or partial expression of the typical PRES pattern, reversibility on follow-up imaging, and a presentation consistent with a clinical neurotoxic syndrome, such as headache, mental status change, or seizure.

A total of 151 patients were identified who had significant clinical neurotoxicity and brain imaging features consistent with PRES. In 23 patients, findings consistent with intracranial hemorrhage of any size were identified, and these patients represented the focus of this report. Institutional review board approval was obtained for this retrospective study.

The clinical inpatient and outpatient records of these patients were comprehensively reviewed for the following: symptoms at presentation, blood pressure at symptomatic toxicity, coagulation measures, and clinical associations, with specific attention paid to identi-
fying clinical features leading to and surrounding the development of PRES. Known associations, including transplant or cyclosporine/Tacrolimus (FK-506) neurotoxic syndrome, infection/sepsis/shock, autoimmune disease, chemotherapy, and eclampsia, were documented. When >1 clinical association was present, the clinically dominant association was used for tabulation. Baseline and toxicity blood pressures were acquired, and mean arterial pressure (MAP = 2/3 diastolic pressure + 1/3 systolic pressure) was calculated at toxicity. Blood pressure was graded at toxicity as 1) normal (MAP ≤ 105 mm Hg), 2) slightly elevated (MAP = 106–115 mm Hg), and 3) significant hypertension (MAP ≥ 116 mm Hg).

Coagulation State
Coagulation state was categorized into 4 subtypes: 1) normal coagulation; 2) intrinsic coagulopathy: intrinsic thrombocytopenia or independent non-medication-induced elevated international normalized ratio (INR), prothrombin time (PT), or partial thromboplastin time (PTT); 3) subtherapeutic anticoagulation: on oral or intravenous medication that may alter platelet function or the coagulation cascade without identifiable change in INR, PT, PTT (ie, aspirin, clopidogrel, subtherapeutic warfarin); 4) therapeutic anticoagulation: on heparin/warfarin with elevated INR, PT, PTT, or thrombocytopenia and platelet/coagulation-altering medications (ie, aspirin, heparin, warfarin). Institutional limits of normal included the following: 1) platelet count <125 × 10^9 µL⁻¹, INR < 1.3, PT < 14.0 seconds, PTT < 35 seconds.

Imaging Evaluation
CT studies were obtained with 2.5- to 5-mm section thickness through the posterior fossa along with 5- to 10-mm section thickness through the supratentorial hemispheres, depending on the study date. Contrast material, when used, consisted of intravenous 150 cc iohexol meglumine (Conray 60; Mallinckrodt, St. Louis Mo), 350 cc iothalamate meglumine (Conray 60; Mallinckrodt, St. Louis Mo), or 125 cc ioversol 350 (Optiray; Mallinckrodt).

MR imaging, when used, was performed at 1.5T and included sagittal and axial T1-weighted images (TR/TE/section/NEX, 600 ms/minimum/5 mm/1) with 5-mm section thickness, spin-echo or fast spin-echo axial proton-density images (TR/TE/section/NEX, 2000–2500 ms/minimum/5/1), T2-weighted images (TR/TE/section/NEX, 2500–3000 ms/84–102 ms/5/1), and T2* multiplanar gradient-echo images (TR/TE/section/NEX, 800 ms/25 ms/5/1.75; flip angle, 20°). Historically, contrast-enhanced T1-weighted images were obtained with 0.1-mmol/kg gadolinium dimeglumine (Magnevist; Berlex Laboratories, Wayne, NJ), gadopentetate (Prohance; Bracco Diagnostics, Princeton Nj), or gadobenate dimeglumine (Multi-hance; Bracco Diagnostics) by using typical T1-weighted parameters as described above. Currently, gadolinium contrast dose is administered, depending on renal function, by using a calculated glomerular filtration rate (GFR) including the following: GFR ≥ 30, full dose; GFR 15–29, half dose; GFR < 15, dialysis after gadolinium administration. Fluid-attenuated inversion recovery (FLAIR) images (TR/TE/T1, 9000–10,000 ms/149 ms/2200 ms), and diffusion-weighted imaging sequences (single-shot echo-planar; TR/TE/section/matrix, 10,000 ms/minimum/5 mm/128) were also available in most patients.

CT/MR Imaging Identification of Hemorrhage
The CT/MR imaging studies were further reviewed for evidence of intracranial hemorrhage. Three types of hemorrhage were noted and tabulated including the following: 1) parenchymal hematoma, 2) subarachnoid blood in cortical sulci, and 3) minute hemorrhages (< 5 mm) in the brain parenchyma. In accordance with standard criteria for CT interpretation, hyperattenuated substrate in either the brain parenchyma or cortical subarachnoid space was considered consistent with hemorrhage. By MR imaging, identification of blood-by-products on standard T1, T2, and FLAIR imaging was dependent on the imaging sequence assessed and expected hemoglobin state. Minute hemorrhages were described when foci of dephasing were <5 mm, consistent with new blood-by-products, typically identified and confirmed on the multi-planar gradient recall sequence.

Statistical Assessment
SAS software (Version 9.1) was used for all analyses (SAS/STAT User’s Guide, 2004; SAS Institute, Cary, NC). All statistical tests were 2-tailed, and statistical significance was set at P < .05. \( \chi^2 \) tests were used to evaluate differences among the proportions of patients with hemorrhage/hemorrhage type according to toxicity blood pressure, clinical association, and coagulation state. When expected frequencies were small, exact tests were used for differences between proportions. The comparisons between coagulation states of the proportion of patients with hemorrhage, adjusting for blood pressure, were conducted by using a logistic regression model.

Results
The results are summarized in Tables 1–4. Intracranial hemorrhage was found in 23 of 151 (15.2%) patients identified with PRES. Seven patients were men and 16 were women (age range, 24–79 years; average, 46 years). Among the 23 patients, confusion or moderate-to-severe altered mentation was the presenting symptom in 8 (35%), with seizures (frequently accompanied by or preceded by headache, vision change, or altered mentation), in 15 (65%).

In the overall data base of 151 patients with PRES, 44 (29.1%) were normotensive, 20 (13.2%) were mildly hypertensive, and 87 (57.6%) were severely hypertensive at toxicity. Clinical associations included the following: posttransplantation/immunosuppression, 50 (33.1%); infection/sepsis/shock, 52 (34.4%); eclampsia/delayed eclampsia, 18 (11.9%); autoimmune disease, 12 (7.9%); postcancer chemotherapy, 10 (6.6%); and nonspecific associations including isolated hypertension, 9 (5.9%).

The frequency of hemorrhage in the typical conditions associated with PRES is summarized in Table 1. Overall, hemorrhage was identified most frequently in patients on immune suppression (22%) and least frequently in patients with eclampsia/delayed eclampsia (5%). When the frequency of hemorrhage in PRES was analyzed considering all tabulated individual clinical associations (ie, solid-organ transplantation, allo-BMT, isolated cyclosporine toxicity, eclampsia, infection/sepsis/shock, autoimmunedisease, postcancer chemotherapy, unknown), a borderline statistical significance in the rate of hemorrhage (P = .07) was identified. The rate of hemorrhage was much greater in patients after allo-BMT (46.6%) compared with those with solid-organ transplantation (11.7%), and this specific difference was statistically significant (P = .02).

Hemorrhage was identified with similar frequency in all blood pressure groups, including 7 of 44 (15.9%) normotensive patients, 3 of 20 (15%) mildly hypertensive patients, and 13 of 87 (14.9%) severely hypertensive patients (Table 3). Toxicity blood pressures varied among the different clinical asso-
ciation categories, but the differences were not statistically significant (Table 1).

The rate of hemorrhage after allo-BMT was high relative to other PRES-associated conditions. Hemorrhage in this clinical group was primarily identified in the severely hypertensive subset. When the patients with allo-BMT were excluded, the incidence of hemorrhage in all blood pressure groups changed to 6 of 37 (16.2%) in normotensive patients, 3 of 19 (15.7%) in mildly hypertensive patients, and 7 of 80 (8.8%) in severely hypertensive patients. These differences were not statistically significant ($P = .34$).

In 16 of 23 (70%) patients with PRES and hemorrhage, neurologic recovery was complete. Average time to resolution of the clinical symptoms that accompanied PRES neurotoxicity was 6.6 days (range, 2–16 days), with average discharge in 15 days (range, 3–76 days). Discharge delay was typically related to the patient’s primary clinical problem and not neurologic sequelae from PRES. Seven of 23 (30%) patients had a poor clinical outcome (Table 2). Six patients died after developing toxicity and PRES with hemorrhage (average survival, 17 days; range, 1–64 days). Four patients recovered or stabilized neurologically but subsequently died from multiorgan dysfunction (MOD) related to their systemic toxicity. One patient developed a hematoma within PRES edema on day 4 and died of herniation and MOD on day 6. A second patient in coma from deep thalamic-striatal minute hemmorhages rec

related to PRES died on day 64 of MOD. In 1 patient with a focal hematoma and minute hemorrhages, a permanent neurologic deficit was present at discharge (hemiparesis, facial droop, hemianopsia).

**Imaging Features**

The imaging features of hemorrhage in the 23 patients with PRES are summarized in Tables 2 and 3 and Figs 1–3. Both CT and MR imaging were available at toxicity in 16 patients, with 4 undergoing CT only and 3, MR only.

In 16 patients, a single hemorrhage type was identified (minute, 6 patients; sulcal, 5 patients; focal hematoma, 5 patients), with combined hemorrhage types identified in 7 patients. Although the numbers are small, an increased incidence in focal hematoma was identified in immunosuppressed patients after allo-BMT (P = 0.02) compared with patients after solid-organ transplantation. Other than this observation, no significant difference was noted between the hemorrhage types and associated clinical conditions in patients with PRES. In addition, no significant difference was noted between the hemorrhage type and blood pressure in patients with PRES neurotoxicity.

In patients with focal hematoma, the hematoma was present at initial imaging in 9 of 11 patients, with delayed hematoma development identified on follow-up imaging in 2 patients (day 2 MR imaging, 1 patient; day 3 CT, 1 patient). Sulcal hemorrhage was identified on the initial imaging study in all 7 patients. In 3 of 12 patients with minute hemorrhage, MR imaging only was performed at toxicity, and findings in all 3 patients were positive. Minute hemorrhages were seen on initial CT scans in 2 of the remaining 9 patients but were identified only on follow-up MR imaging in 7 of 9 patients (day 1 MR imaging, 2 patients; day 2 MR imaging, 5 patients).

**Coagulation State**

Coagulation data were available in 150 of 151 patients with PRES. The impact of coagulation state on hemorrhage in PRES is summarized in Table 4. In patients with hemorrhage, 10 of 23 (43%) had normal coagulation, with 13 of 23 (57%) categorized in 1 of the 3 abnormal groups. In the 127 patients without hemorrhage, 68 (53.4%) had normal coagulation, with 59 (46.5%) in 1 of the 3 abnormal coagulation groups. The overall difference in coagulation state between the hemorrhage and nonhemorrhage PRES patients was not statistically significant.

Therapeutic anticoagulation was present in 4 of 23 (17.4%) patients with PRES and hemorrhage, compared with 6 of 127 (6.7%) patients without hemorrhage (Table 4). This difference was statistically significant when compared to patients with normal coagulation (P = 0.04) and borderline in signifi-
cance when stratified for blood pressure ($P = .06$). Patients in this group underwent the following treatments: heparin drip with elevated PTT (4 patients), warfarin with elevated INR (2 patients), heparin drip with thrombocytopenia (1 patient), and baby aspirin with thrombocytopenia (3 patients).

Intrinsic coagulopathy was present in 8 of 23 (34.8%) patients with hemorrhage and 37 of 127 (29.1%) patients without hemorrhage. All patients with thrombocytopenia in the hemorrhage group had platelet counts below $80 \times 10^3$/$\mu$L$^{-1}$. Subtherapeutic anticoagulation was present in 1 normotensive patient with hemorrhage (on clopidogrel at toxicity; platelet count/coagulation levels, normal) and 16 patients without hemorrhage. These coagulation states were not statistically significant when compared with those in patients with normal coagulation.

**Discussion**

The mechanism behind PRES remains controversial and unproven. Severe hypertension leading to a blood pressure that exceeds the upper limits of autoregulation, with subsequent forced hyperperfusion, has been suggested. Conversely,
vasculopathy and hypoperfusion have been reported, and the PRES imaging appearance resembles a watershed distribution. Potential etiologic factors include endothelial injury/dysfunction with alteration of the blood-brain barrier, as is present in eclampsia, or other causes, such as conditioning regimens before transplantation, effects of graft-versus-host disease, or the results of the immunosuppressive drugs cyclosporine and tacrolimus.

Prior studies have demonstrated parenchymal hematoma or sulcal subarachnoid hemorrhage in 5%–17% of patients with PRES, but the mechanism behind hemorrhage in PRES is equally unclear. Doss-Esper et al have proposed two hypotheses: 1) nonaneurysmal subarachnoid (sulcal) hemorrhage due to rupture of pial vessels in the face of severe hypertension and impaired cerebral autoregulation, and 2) post-ischemic reperfusion injury leading to multifocal brain hemmorhages.

Although the incidence of hemorrhage in our PRES population (15.2%) is similar to that in previous reports, our data demonstrate a number of new and important observations.

**Associated Clinical Conditions**

There was a borderline difference in the incidence of hemorrhage in PRES between the different toxicity-associated conditions (P = .07), with the highest rate seen in the setting of immunosuppression (22%) and the lowest rate, in eclampsia (5.5%). PRES-related hemorrhage was statistically more common (P = .02) in the allo-BMT subgroup (46.6%) compared with patients with solid-organ transplants (11.7%), and this difference likely accounts for the overall high rate in the immunosuppression group.

The reason for the high rate of PRES-related hemorrhage in the allo-BMT subgroup is not clear. The incidence of PRES or cyclosporine toxicity after allo-BMT is known to be significant. Allo-BMT is also known to be a complex clinical state with multiple systemic challenges: graft-versus-host effects, veno-occlusive disease, bone marrow transplant thrombotic microangiopathy, and opportunistic infection. The immunosuppressive drugs cyclosporine and tacrolimus are typically administered at higher dose levels after allo-BMT for control of graft-versus-host disease, and these drugs can potentially augment toxicity through systemic effects.

Cyclosporine and tacrolimus can cause direct endothelial injury, and the immunosuppressive drugs inhibit T-cell function, with a resultant altered immune response and increased risk of infection. Cyclosporine is also known to induce vasoconstriction through endothelial cell production and release of endothelin and systemic sympathetic stimulation. Systemic/renal vasoconstriction with resultant hypertension could lead to reduced cerebral blood flow due to autoregulatory vasoconstriction. In addition, these drugs could reduce cerebral blood flow directly, secondary to cerebral vasconstriction. The combined effects might lead to increased but complex cerebral vascular instability, with an increased risk of hemorrhage.

**Presence of Hypertension**

Our data fail to demonstrate a relationship between PRES-related hemorrhage and moderate or severe hypertension at toxicity. No statistical difference in the incidence of hemorrhage was appreciated when the toxicity association was evaluated relative to blood pressure category (Table 1) or hemorrhage type (Table 2) in the overall population. Therefore, in the overall population, blood pressure does not appear to affect the incidence of hemorrhage in PRES, and hemorrhage type appears to occur with similar frequency among the different PRES toxicity-associated conditions.

Of interest, although not statistically significant, the incidence of hemorrhage was markedly less in the severely hypertensive subset (8.8%) when the unique allo-BMT subgroup was excluded. The extent of PRES vasogenic edema has previously been found to be less in severely hypertensive patients who developed PRES in association with infection/sepsis/shock. Similarly, the extent of PRES vasogenic edema was less in patients after liver transplantation (typically lower MAP at toxicity) compared with PRES after kidney transplantation (typically high MAP at toxicity). Observations in patients with PRES who present with severe hypertension (less vasogenic edema, no increase in hemorrhage rate) bring into question whether severe hypertension is a direct cause of PRES neurotoxicity. The role of hypertension in PRES may be more complex than previously considered.

Also of interest, hemorrhage was equally common (15.9%) in the normotensive patients who developed PRES. While controversial, hypoperfusion has been demonstrated in PRES. Vasoconstriction of medium and large size vessels has been documented in patients with PRES and single-photon emission tomography, MR perfusion, and CT perfusion have demonstrated hypoperfusion. Vasoconstriction coupled with blood pressure instability could predispose to reperfusion injury as occurs in patients following subarachnoid hemorrhage. Our observations might be consistent with the previously stated theory of postischemic reperfusion as a potential cause of hemorrhage in PRES. In addition, lymphocyte trafficking has been noted in PRES, and recently, direct histologic evidence of endothelial activation, T-cell dysfunction, and brain hypoxia has been demonstrated with upregulated endothelial/cellular vascular endothelial growth factor in reversible encephalopathy posttransplantation.

Hemorrhage may be seen in the setting of reperfusion injury, as can develop after stroke thrombolysis or spontaneous embolus recanalization. Small areas of focal petechial hemorrhage into an infarct bed are common in embolic infarction (hemorrhagic infarction). In thrombolysis-related reperfusion injury, both small petechial hemorrhages and focal hematoma can be observed. The mechanism of reperfusion injury is complex and appears to involve elements of both ischemic capillary injury and immune cellular reaction. Similar to the observations in hemorrhagic transformation of infarction, in which poor outcome is generally related to the development of a significant focal hematoma, clinical outcome in most of our patients with PRES was not affected by the identification of hemorrhage. Regions of both infarction and hemorrhage are also known to develop in the setting of cerebral vasoconstriction or vasospasm. In aneurysmal subarachnoid hemorrhage, early vasospasm can occur with infarction and both petechial blood and focal hematoma formation. In the reversible cerebral vasoconstric-
Conclusions

The incidence of hemorrhage in our patients with PRES parallels that in previous reports (15.2%), with 3 types of hemorrhage noted, minute, sulcal subarachnoid, and focal hematoma. A borderline difference in the hemorrhage rate was seen among the various clinical conditions associated with PRES (P = .07), the greatest noted after transplantation and the least in association with eclampsia or delayed eclampsia. In patients with transplants, the frequency of hemorrhage was significantly greater (P = .02) after allo-BMT (46.6%) compared with solid-organ transplantation (11.7%) and the presence of focal hematoma was statistically more common in the allo-BMT group (P = .02). The incidence of hemorrhage was also greater (P = .04) in patients therapeutically anticoagulated at neurotoxicity.

No difference in the incidence of the 3 hemorrhage types (minute, subarachnoid, and hematoma) was seen with respect to the associated clinical condition or presence of hypertension at toxicity. Severe hypertension at toxicity did not influence the frequency of hemorrhage in PRES in the overall population, but when the unique allo-BMT subgroup was excluded, the incidence of hemorrhage was less (8.8%) in the severely hypertensive subset.
References


38. Prince JW, McDonald WI, Franklin RJM. Demyelinating diseases. In: Graham...
63. Dale RC. Acute disseminated encephalomyelitis. Semin Pediatr Infect Dis 2003;14:90–95